This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.




Factor Xa

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
<StructureSection load='2PR3' size='350' side='right' scene='' caption='Human factor X heavy chain (grey) and light chain (green) complex with pyrrolydine derivative inhibitor and Ca+2 ions (green) (PDB code [[2pr3]])'>
<StructureSection load='2PR3' size='350' side='right' scene='' caption='Human factor X heavy chain (grey) and light chain (green) complex with pyrrolydine derivative inhibitor and Ca+2 ions (green) (PDB code [[2pr3]])'>
[[Image:Coagulation full.svg.png|thumb|450px|The coagulation cascade.]]
[[Image:Coagulation full.svg.png|thumb|450px|The coagulation cascade.]]
-
 
+
__TOC__
==Introduction==
==Introduction==
'''Factor X''' is a vitamin K-dependent [http://en.wikipedia.org/wiki/Glycoprotein glycoprotein] that is synthesized in the liver. [http://en.wikipedia.org/wiki/Zymogen Zymogen] factor X circulates in plasma as a 2 chain molecule composed of a disulfide linked light chain (Mr = 16500) and heavy chain (Mr = 42,000). Factor X is activated to '''factor Xa''' by cleavage of the activation peptide. This reaction is catalyzed by [http://en.wikipedia.org/wiki/Factor_VIIa factor VIIa]-[http://en.wikipedia.org/wiki/Tissue_factor tissue factor] (extrinsic Xase complex) and [http://en.wikipedia.org/wiki/Factor_ixa factor IXa]-[http://en.wikipedia.org/wiki/Factor_viiia factor VIIIa] (intrinsic Xase complex).<ref name="Greer">Greer, John (2008). ''Wintrobe's Clinical Hematology'', p. 545-546. Lippincott Williams & Wilkins. ISBN 0781765072.</ref>
'''Factor X''' is a vitamin K-dependent [http://en.wikipedia.org/wiki/Glycoprotein glycoprotein] that is synthesized in the liver. [http://en.wikipedia.org/wiki/Zymogen Zymogen] factor X circulates in plasma as a 2 chain molecule composed of a disulfide linked light chain (Mr = 16500) and heavy chain (Mr = 42,000). Factor X is activated to '''factor Xa''' by cleavage of the activation peptide. This reaction is catalyzed by [http://en.wikipedia.org/wiki/Factor_VIIa factor VIIa]-[http://en.wikipedia.org/wiki/Tissue_factor tissue factor] (extrinsic Xase complex) and [http://en.wikipedia.org/wiki/Factor_ixa factor IXa]-[http://en.wikipedia.org/wiki/Factor_viiia factor VIIIa] (intrinsic Xase complex).<ref name="Greer">Greer, John (2008). ''Wintrobe's Clinical Hematology'', p. 545-546. Lippincott Williams & Wilkins. ISBN 0781765072.</ref>
Line 88: Line 88:
**[[2ra0]], [[2p3t]], [[2p16]], [[2p3u]], [[2pr3]], [[2q1j]], [[2g00]], [[2fzz]], [[2bq6]], [[2bq7]], [[2bqw]], [[1z6e]], [[2bmg]], [[2bok]], [[1mq5]], [[1mq6]], [[1fjs]], [[3k9x]], [[3ffg]], [[3kl6]], [[3hpt]], [[2vvc]], [[2vvu]], [[2vvv]], [[2vwl]], [[2vwm]], [[2vwn]], [[2vwo]], [[2w3i]], [[2w3k]], [[2jkh]], [[3ens]], [[2vh6]], [[2vh0]], [[2w26]], [[3cs7]], [[3cen]], [[2phb]], [[2y7x]], [[2y7z]], [[2y80]], [[2y81]], [[2y82]], [[2wyg]], [[2wyj]], [[2xbv]], [[2xbw]], [[2xbx]], [[2xby]], [[1ioe]], [[1iqe]], [[1iqf]], [[1iqg]], [[1iqh]], [[1iqi]], [[1iqj]], [[1iqk]], [[1iql]], [[1iqm]], [[1iqn]], [[1g2l]], [[1g2m]], [[1xka]], [[1xkb]], [[1fax]], [[2y5f]], [[2y5g]], [[2y5h]], [[3q3k]], [[4a7i]], [[3m36]], [[3m37]], [[3tk5]], [[3tk6]], [[2xc0]], [[2xc4]], [[2xc5]], [[3iit]], [[3kqb]], [[3kqc]], [[3kqd]], [[3kqe]], [[3liw]], [[4y6d]], [[4y71]], [[4y76]], [[4y79]], [[4y7a]], [[4y7b]] - hFX heavy chain catalytic domain + light chain EGF-like domain + inhibitor<br />
**[[2ra0]], [[2p3t]], [[2p16]], [[2p3u]], [[2pr3]], [[2q1j]], [[2g00]], [[2fzz]], [[2bq6]], [[2bq7]], [[2bqw]], [[1z6e]], [[2bmg]], [[2bok]], [[1mq5]], [[1mq6]], [[1fjs]], [[3k9x]], [[3ffg]], [[3kl6]], [[3hpt]], [[2vvc]], [[2vvu]], [[2vvv]], [[2vwl]], [[2vwm]], [[2vwn]], [[2vwo]], [[2w3i]], [[2w3k]], [[2jkh]], [[3ens]], [[2vh6]], [[2vh0]], [[2w26]], [[3cs7]], [[3cen]], [[2phb]], [[2y7x]], [[2y7z]], [[2y80]], [[2y81]], [[2y82]], [[2wyg]], [[2wyj]], [[2xbv]], [[2xbw]], [[2xbx]], [[2xby]], [[1ioe]], [[1iqe]], [[1iqf]], [[1iqg]], [[1iqh]], [[1iqi]], [[1iqj]], [[1iqk]], [[1iql]], [[1iqm]], [[1iqn]], [[1g2l]], [[1g2m]], [[1xka]], [[1xkb]], [[1fax]], [[2y5f]], [[2y5g]], [[2y5h]], [[3q3k]], [[4a7i]], [[3m36]], [[3m37]], [[3tk5]], [[3tk6]], [[2xc0]], [[2xc4]], [[2xc5]], [[3iit]], [[3kqb]], [[3kqc]], [[3kqd]], [[3kqe]], [[3liw]], [[4y6d]], [[4y71]], [[4y76]], [[4y79]], [[4y7a]], [[4y7b]] - hFX heavy chain catalytic domain + light chain EGF-like domain + inhibitor<br />
**[[2boh]] - hFX heavy chain catalytic domain (mutant) + light chain EGF-like domain (mutant) + inhibitor<br />
**[[2boh]] - hFX heavy chain catalytic domain (mutant) + light chain EGF-like domain (mutant) + inhibitor<br />
-
**[[2uwo]], [[2uwp]], [[2uwl]], [[2j94]], [[2j95]], [[2j2u]], [[2j34]], [[2j38]], [[2j4i]], [[2cji]], [[1lqd]], [[1lpg]], [[1lpk]], [[1lpz]], [[1ksn]], [[1ezq]], [[1f0r]], [[1f0s]] - hFX heavy chain catalytic domain + light chain GLA and EGF-like domains 46-179 + inhibitor<br />
+
**[[2uwo]], [[2uwp]], [[2uwl]], [[2j94]], [[2j95]], [[2j2u]], [[2j34]], [[2j38]], [[2j4i]], [[2cji]], [[1lqd]], [[1lpg]], [[1lpk]], [[1lpz]], [[1ksn]], [[1ezq]], [[1f0r]], [[1f0s]], [[4zh8]], [[4zha]], [[5k0h]] - hFX heavy chain catalytic domain 235-488 + light chain GLA and EGF-like domains 46-179 + inhibitor<br />
**[[1nfu]], [[1nfw]], [[1nfx]], [[1nfy]] - hFX heavy chain catalytic domain + light chain residues 46-240 + inhibitor<br />
**[[1nfu]], [[1nfw]], [[1nfx]], [[1nfy]] - hFX heavy chain catalytic domain + light chain residues 46-240 + inhibitor<br />
**[[3sw2]], [[4bti]], [[4btt]], [[4btu]] - hFX heavy chain catalytic domain + light chain residues 84-179 + inhibitor<br />
**[[3sw2]], [[4bti]], [[4btt]], [[4btu]] - hFX heavy chain catalytic domain + light chain residues 84-179 + inhibitor<br />

Revision as of 09:12, 27 February 2023

Human factor X heavy chain (grey) and light chain (green) complex with pyrrolydine derivative inhibitor and Ca+2 ions (green) (PDB code 2pr3)

Drag the structure with the mouse to rotate

3D structures of factor Xa

Updated on 27-February-2023

Additional Resources

For additional information, see: Hemophilia

References

  1. 1.0 1.1 Greer, John (2008). Wintrobe's Clinical Hematology, p. 545-546. Lippincott Williams & Wilkins. ISBN 0781765072.
  2. 2.0 2.1 Department of Chemistry, University of Maine, Orono, ME. http://chemistry.umeche.maine.edu/CHY252/Peptidase3.html
  3. Padmanabhan K, Padmanabhan KP, Tulinsky A, Park CH, Bode W, Huber R, Blankenship DT, Cardin AD, Kisiel W. Structure of human des(1-45) factor Xa at 2.2 A resolution. J Mol Biol. 1993 Aug 5;232(3):947-66. PMID:8355279 doi:http://dx.doi.org/10.1006/jmbi.1993.1441
  4. Friedman PA, Przysiecki CT. Vitamin K-dependent carboxylation. Int J Biochem. 1987;19(1):1-7. PMID:3106112
  5. Vermeer C. Gamma-carboxyglutamate-containing proteins and the vitamin K-dependent carboxylase. Biochem J. 1990 Mar 15;266(3):625-36. PMID:2183788
  6. Price PA, Fraser JD, Metz-Virca G. Molecular cloning of matrix Gla protein: implications for substrate recognition by the vitamin K-dependent gamma-carboxylase. Proc Natl Acad Sci U S A. 1987 Dec;84(23):8335-9. PMID:3317405
  7. Freedman SJ, Furie BC, Furie B, Baleja JD. Structure of the metal-free gamma-carboxyglutamic acid-rich membrane binding region of factor IX by two-dimensional NMR spectroscopy. J Biol Chem. 1995 Apr 7;270(14):7980-7. PMID:7713897
  8. Freedman SJ, Blostein MD, Baleja JD, Jacobs M, Furie BC, Furie B. Identification of the phospholipid binding site in the vitamin K-dependent blood coagulation protein factor IX. J Biol Chem. 1996 Jul 5;271(27):16227-36. PMID:8663165
  9. Morita T, Jackson CM. Preparation and properties of derivatives of bovine factor X and factor Xa from which the gamma-carboxyglutamic acid containing domain has been removed. J Biol Chem. 1986 Mar 25;261(9):4015-23. PMID:3512564
  10. Muskavitch MA, Hoffmann FM. Homologs of vertebrate growth factors in Drosophila melanogaster and other invertebrates. Curr Top Dev Biol. 1990;24:289-328. PMID:2116263
  11. Ohlin AK, Linse S, Stenflo J. Calcium binding to the epidermal growth factor homology region of bovine protein C. J Biol Chem. 1988 May 25;263(15):7411-7. PMID:3259233
  12. Selander-Sunnerhagen M, Ullner M, Persson E, Teleman O, Stenflo J, Drakenberg T. How an epidermal growth factor (EGF)-like domain binds calcium. High resolution NMR structure of the calcium form of the NH2-terminal EGF-like domain in coagulation factor X. J Biol Chem. 1992 Sep 25;267(27):19642-9. PMID:1527084
  13. Persson E, Hogg PJ, Stenflo J. Effects of Ca2+ binding on the protease module of factor Xa and its interaction with factor Va. Evidence for two Gla-independent Ca(2+)-binding sites in factor Xa. J Biol Chem. 1993 Oct 25;268(30):22531-9. PMID:8226763
  14. Persson E, Selander M, Linse S, Drakenberg T, Ohlin AK, Stenflo J. Calcium binding to the isolated beta-hydroxyaspartic acid-containing epidermal growth factor-like domain of bovine factor X. J Biol Chem. 1989 Oct 5;264(28):16897-904. PMID:2789221
  15. Hopfner KP, Kopetzki E, Kresse GB, Bode W, Huber R, Engh RA. New enzyme lineages by subdomain shuffling. Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):9813-8. PMID:9707558
  16. Factor X. Wikipedia
  17. Serine Protease. Wikipedia
  18. 18.0 18.1 Hedstrom L. Serine protease mechanism and specificity. Chem Rev. 2002 Dec;102(12):4501-24. PMID:12475199
  19. 19.0 19.1 Rai R, Sprengeler PA, Elrod KC, Young WB. Perspectives on factor Xa inhibition. Curr Med Chem. 2001 Feb;8(2):101-19. PMID:11172669
  20. www.bmolchem.wisc.edu/
  21. 21.0 21.1 Bachovchin, W. Contributions of NMR spectroscopy to the study of hydrogen bonds in serine protease active sites. Magnetic Resonance in Chemistry; (2001); 39(Spec. Issue); 199-213.
  22. Bachovchin WW. 15N NMR spectroscopy of hydrogen-bonding interactions in the active site of serine proteases: evidence for a moving histidine mechanism. Biochemistry. 1986 Nov 18;25(23):7751-9. PMID:3542033
  23. Brady K, Wei AZ, Ringe D, Abeles RH. Structure of chymotrypsin-trifluoromethyl ketone inhibitor complexes: comparison of slowly and rapidly equilibrating inhibitors. Biochemistry. 1990 Aug 21;29(33):7600-7. PMID:2271520
  24. Frey PA, Whitt SA, Tobin JB. A low-barrier hydrogen bond in the catalytic triad of serine proteases. Science. 1994 Jun 24;264(5167):1927-30. PMID:7661899
  25. Frey, Perry A. Strong hydrogen bonding in chymotrypsin and other serine proteases. Journal of Physical Organic Chemistry (2004), 17(6-7), 511-520.
  26. 26.0 26.1 Fuhrmann CN, Daugherty MD, Agard DA. Subangstrom crystallography reveals that short ionic hydrogen bonds, and not a His-Asp low-barrier hydrogen bond, stabilize the transition state in serine protease catalysis. J Am Chem Soc. 2006 Jul 19;128(28):9086-102. PMID:16834383 doi:http://dx.doi.org/10.1021/ja057721o
  27. Kuhn P, Knapp M, Soltis SM, Ganshaw G, Thoene M, Bott R. The 0.78 A structure of a serine protease: Bacillus lentus subtilisin. Biochemistry. 1998 Sep 29;37(39):13446-52. PMID:9753430 doi:10.1021/bi9813983
Personal tools